Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo

Journal of Biological Chemistry

Volumn 289, Issue 46, 2014, Pages 31879-31890

  Kumar Keerthy, Hosadurga ^a   Mohan, Chakrabhavi Dhananjaya ^b   Siveen, Kodappully Sivaraman ^c   Fuchs, Julian E ^d   Rangappa, Shobith ^e   Sundaram, Mahalingam S ^b   Li, Feng ^c   Girish, Kesturu S ^b,g   Sethi, Gautam ^c,f   Basappa, ^a,h   Bender, Andreas ^d   Rangappa, Kanchugarakoppal Subbegowda ^b  

^a BANGALORE UNIVERSITY   (India)

^b UNIVERSITY OF MYSORE   (India)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g TUMKUR UNIVERSITY   (India)

^h KARNATAK UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CELL CULTURE; MACROPHAGES; MAMMALS; MOLECULAR DYNAMICS;

ANTICANCER ACTIVITIES; EXPERIMENTAL VALIDATIONS; HEPATOCELLULAR CARCINOMA; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISORDERS; MOLECULAR DYNAMICS SIMULATIONS; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTORS;

DISEASES;

3,3' [(2 BUTYL 5 CHLORO 1H IMIDAZOL 4 YL)METHYLENE]BIS(4 HYDROXY 2H CHROMEN 2 ONE); ANTINEOPLASTIC AGENT; BISCOUMARIN DERIVATIVE; CYCLIN D1; ETANERCEPT; HEPARIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; COUMARIN DERIVATIVE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; COLITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MIGRATION INHIBITION; MITOSIS INHIBITION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DISEASE MODEL; DRUG DESIGN; DRUG EFFECTS; IC50; INFLAMMATORY BOWEL DISEASE; LIVER CELL; LIVER NEOPLASMS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SURFACE PLASMON RESONANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARCINOMA, HEPATOCELLULAR; COUMARINS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG DESIGN; HEP G2 CELLS; HEPATOCYTES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MOLECULAR DOCKING SIMULATION; NF-KAPPA B; PROTEIN BINDING; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910672931     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.593855     Document Type: Article

References (59)

1. Hehlgans, T., and Pfeffer, K. (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115,1-20
2. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 72, 3666-3670
3. Bradley, J. R. (2008) TNF-mediated inflammatory disease.J. Pathol. 214, 149-160
4. Hawes, A. S., Fischer, E., Marano, M. A., Van Zee, K. J., Rock, C. S., Lowry, S. F., Galvano, S. E., and Moldawer, L. L. (1993) Comparison of periphera.J.blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 a administration: studies using a nove.J.interleuldn-1 receptor antagonist. Ann. Surg. 218, 79-90
5. Locksley, R. M., Killeen, N., and Lenardo, M. J. (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cel.J.104, 487-501
6. Wu, Y., and Zhou, B.P. (2010) TNF-α/NF-KB/Snail pathway in cancer cell migration and invasion. Br.J. Cancer 102, 639-644
7. Chemical Computing Group Inc. (2013) Molecular Operating Environment (MOE), Chemical Computing Group Inc., Montreal, Quebec H3A 2R7, Canada
8. Nemchenko, A., and Hill, J. A. (2010) NEMO nuances NF-KB. Circ. Res. 106,10-12
9. Sethi, G., and Tergaonkar, V. (2009) Potential pharmacological control of the NF-KB pathway. Trends Pharmacol. Sci. 30, 313-321
10. Li, F., and Sethi, G. (2010) Targeting transcription factor NF-KB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 1805,167-180
11. Sasaki, C. Y., Barberi, T. J., Ghosh, P., and Longo, D. L. (2005) Phosphorylation of RelA/p65 on serine 536 defines an IKBa-independent NF-kB pathway. J. Biol. Chem. 280, 34538-34547
12. Nabel, G. J., and Verma, I. M. (1993) Proposed NF-KB/IKB family nomenclature. Genes Dev. 7, 2063
13. Shrimali, D., Shanmugam, M. K., Kumar, A. P., Zhang, J., Tan, B. K., Ahn, K. S., and Sethi, G. (2013) Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 341, 139-149
14. Sethi, G., Sung, B., Kunnumakkara, A. B., and Aggarwal, B. B. (2009) Targeting TNF for treatment of cancer and autoimmunity. Adv. Exp. Med. Biol. 647, 37-51
15. Siddiqui, A. M., Cui, X., Wu, R., Dong, W., Zhou, M., Hu, M., Simms, H. H., and Wang, P. (2006) The anti-inflammatory effect of cur cumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor. Urit. Care Med. 34,1874-1882
16. Essayan, D. M. (2001) Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671-680
17. Snir, O., Hesselberg, E., Amoudruz, P., Klareskog, L., Zarea-Ganji, I., Catrina, A. L, Padyukov, L., Malmström, V., and Seddighzadeh, M. (2013) Genetic variation in the serotonin receptor gene affects immune responses in rheumatoid arthritis. Genes Immun. 14, 83-89
18. Basappa, Murugan, S., Kavitha, C. V., Purushothaman, A., Nevin, K. G., Sugahara, K., and Rangappa, K. S. (2010) A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HBEGF, and TNF-a. Cancer Lett. 297, 231-243
19. Tanaka, T., Hishitani, Y., and Ogata, A. (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologies 8,141-153
20. Alli-Akintade, L., Pruthvi, P., Hadi, N., and Sachar, D. (2014) Race and fistulizing perianal Crohn's disease.J. Clin. Gastroenterol. 10.1097/MCG. 0000000000000117
21. Dasgupta, B., Combe, B., Louw, I., Wollenhaupt, J., Zerbini, C. A., Beaulieu, A., Schulze-Koops, H., Durez, P., Wolff, V., Yao, R., Weng, H. H., Govoni, M., and Vastesaeger, N. (2014) Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes. Arthritis Care Res. (Hoboken) 10.1002/acr.22371
22. Kobayashi, T., Yokoyama, T., Ito, S., Kobayashi, D., Yamagata, A., Okada, M., Oofusa, K., Narita, L, Murasawa, A., Nakazono, K., and Yoshie, H. (2014) Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor Adalimumab.J. Periodontal. 10.1902/jop.2014.140194
23. Rüngeler, P., Castro, V., Mora, G., Gören, N., Vichnewski, W., Pahl, H. L., Merfort, I., and Schmidt, T. J. (1999) Inhibition of transcription factor NF-KB by sesquiterpene lactones: a proposed molecular mechanism of action. Bioorg. Med. Chem. 7, 2343-2352
24. Kumar, B., Paricharak, S., Dinesh, K. R., Sivaraman Siveen, K., Fuchs, J., Rangappa, S., Mohan, C. D., Mohandas, N., Kumar, A. P., Sethi, G., Bender, A., Basappa, S., and Rangappa, K. S. (2014) Synthesis, biological evaluation and in silico and in vitro mode-of-action analysis of novel dihydropyrímídones targeting PPAR-7. RSCAdv. 4, 45143-45146
25. Basappa, Sugahara, K., Thimmaiah, K. N., Bid, H. K., Houghton, P. J., and Rangappa, K. S. (2012) Anti-tumor activity of a novel hS-mimetic-vascular endothelial growth factor binding small molecule. PLoS One 7, e39444
26. Fongmoon, D., Shetty, A. K., Basappa, Yamada, S., Sugiura, M., Kongtawelert, P., and Sugahara, K. (2007) Chondroitinase-mediated degradation of rare 3-O-sulfated glucuronic acid in functional oversulfated chondroitin sulfate K and E.J. Biol. Chem. 282, 36895-36904
27. He, M. M., Smith, A. S., Oslob, J. D., Flanagan, W. M., Braisted, A. C, Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., Fung, A. D., Farrington, G., Eldredge, J. K., Day, E. S., Cruz, L. A., Cachero, T. G., Miller, S. K., Friedman, J. E., Choong, I. C, and Cunningham, B. C. (2005) Small-molecule inhibition of TNF-α. Science 310,1022-1025
28. Revanna, C., SivaramanáSiveen, K., and NanjundaáSwamy, S. (2014) Synthesis and biological evaluation of tetrahydropyridinepyrazoles ('PFPs') as inhibitors of STATS phosphorylation. MedChemComm 5, 32-40
29. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., and Case, D. A. (2004) Development and testing of a general amber force field.J. Comput. Chem. 25,1157-1174
30. Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Montgomery, J., J. A., Vreven, T., Kudin, K. N., Burant, J. C., Millam, J. M., Iyengar, S. S., Tomasi, J., Barone, V., Mennucci, B., Cossi, M., Scalmani, G., Rega, N., Petersson, G. A., Nakatsuji, H., Hada, M., Eh ara, M., Toyota, K., Fukuda, R., Hasegawa, J., shida, M., Nakajima, T., Honda, Y., Kitao, O., Nalcai, H., Kiene, M., Li, X., Knox, J. E., Hratchian, H. P., Cross, J. B., Bakken, V., Adamo, C., Jar amillo, J., Gomperts, R., Stratmann, R. E., Yazyev, O., Austin, A. J., Cammi, R., Pomelli, C., OchtersKi, J. W., Ayala, P. Y., Morokuma, K., Voth, G. A., Salvador, P., Dannenberg, J. J., Zakrzewski, V. G., Dapprich, S., Daniels, A. D., Strain, M. C., Farkas, O., Malick, D. K., Rabuck, A. D., Raghavachari, K., Foresman, J. B., Ortiz, J. V., Cui, Q., Baboul, A. G., Clifford, S., Cioslowski, J., Stefanov, B. B., Liu, G., Liashenko, A., Piskorz, P., Komaromi, L, Martin, R. L., Fox, D. J., Keith, T., Al-Laham, M. A., Peng, C. Y., Nanayakkara, A., Challacombe, M., Gill, P. M. W., Johnson, B., Chen, W., Wong, M. W., Gonzalez, C., and Pople, J. A. (2004) Gaussian 03, Revision C, 02 Ed., Gaussian, Inc., Wallingford, CT
31. Bayly, C. L, Cieplak, P., Cornell, W., and Kollman, P. A. (1993) A wellbehaved electrostatic potential based method using charge restraints for deriving atomic charges: theRESP model.J Phys. Chem. 97,10269-10280
32. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935
33. Lindorff-Larsen, K., Piaña, S., Palmo, K., Maragakis, P., Klepeis, J. L., Dror, R. O., and Shaw, D. E. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78,1950-1958
34. Le Grand, S., Götz, A. W., and Walker, R. C. (2013) SPFP: Speed without compromise: a mixed precision model for GPU accelerated molecular dynamics simulations. Comput. Phys. Commun. 184, 374-380
35. Fuchs, J. E., Huber, R. G., von Grafenstein, S., Wallnoefer, H. G., Spitzer, G. M., Fuchs, D., and Liedl, K. R. (2012) Dynamic regulation of phenylalanine hydroxylase by simulated redox manipulation. PLoS One 7, e53005
36. Basappa, Murugan, S., Sugahara, K. N., Lee, C. M., ten Dam, G. B., van Kuppevelt, T. H., Miyasaka, M., Yamada, S., and Sugahara, K. (2009) In-volvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology 19, 735-742
37. Pettipher, E. R., Labasi, J. M., Salter, E. D., Stam, E. J., Cheng, J. B., and Griffiths, R. J. (1996) Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram. Br. J. Pharmacol. 117, 1530-1534
38. Cooper, H. S., Murthy, S. N., Shah, R. S., and Sedergran, D. J. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238-249
39. Gonzalez-Rey, E., Chorny, A., and Delgado, M. (2006) Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130,1707-1720
40. Liu, J., Feng, Z., Xu, J., Wang, Y., and Zhang, P. (2007) Rare biscoumarins and a chlorogenic acid derivative from Erycibe obtusifolia. Phytochemistry 68,1775-1780
41. Hagiwara, H., Fujimoto, N., Suzuki, T., and Ando, M. (2000) Synthesis of methylenebis(4-hydroxy-2-pyrone) or methylenebis(4-hydroxycoumarin) derivatives by organic solid state reaction. Heterocycles 53, 549-552
42. Mehrabi, H., and Abusaidi, H. (2010) Synthesis of biscoumarin and 3,4-dihydropyrano[c] chromene derivatives catalysed by sodium dodecyl sul-fate (SDS) in neat water. J Iran. Chem. Soc. 7, 890-894
43. Cravotto, G., Nano, G. M., Palmisano, G., and Tagliapietra, S. (2003) The reactivity of 4-hydroxycoumarin under heterogeneous high-intensity sonochemical conditions. Synthesis 2003,1286-1291
44. Mohd Fauzi, F., Koutsoukas, A., Lowe, R., Joshi, K., Fan, T.-P., Glen, R. C., and Bender, A. (2013) Chemogenomics approaches to rationalizing the mode-of-action of traditional Chinese and ayurvedic medicine J. Chem. Inf. Model. 53, 661-673
45. Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glide, M., Glen, R. C., and Bender, A. (2011) From in silico target prediction to multi-target drug design: Current databases, methods and applications.J. Proteomics 74, 2554-2574
46. Koutsoukas, A., Lowe, R., Kalantarmotamedi, Y., Mussa, H. Y., Klaffke, W., Mitchell, J. B. O., Glen, R. C., and Bender, A. (2013) In silico target predictions: defining a benchmarking data set and comparison of performance of the multiclass naive Bayes and Parzen-Rosenblatt window. J. Chem. Inf. Model. 53,1957-1966
47. Rath, P. C., and Aggarwal, B. B. (1999) TNF-induced signaling in apoptosis.J. Clin. Immunol. 19, 350-364
48. van Horssen, R., Ten Hagen, T. L., and Eggermont, A. M. (2006) TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397-408
49. Takahashi, S., Hakuta, M., Aiba, K., Ito, Y., Horikoshi, N., Miura, M., Hatake, K., and Ogata, E. (2003) Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr.-Relat. Cancer 10, 403-407
50. Askling, J., van Vollenhoven, R. F., Granath, F., Raaschou, P., Fored, C. M., Baecklund, E., Dackhammar, C., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., Rantapää-Dahlqvist, S., Saxne, T., and Klareskog, L. (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor a therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 60, 3180-3189
51. Kim, H. Y., Park, E. J., Joe, E.-H., and Jou, I. (2003) Cur cumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol. 171, 6072-6079
52. Olivier, S., Robe, P., and Bours, V. (2006) Can NF-KB be a target for novel and efficient anti-cancer agents? Biochem. Pharmacol. 72,1054-1068
53. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., and Kollias, G. (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031
54. Iqbal, M., Verpoorte, R., Korthout, H. A. J., and Mustafa, N. (2013) Phytochemicals as a potential source for TNF-α inhibitors. Phytochem. Rev. 12, 65-93
55. Singh, S., and Aggarwal, B. B. (1995) Activation of transcription factor NF-KB is suppressed by cur cumin (diferuloylmethane). J. Biol. Chem. 270, 24995-25000
56. Chen, Y. R., and Tan, T. H. (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by cur cumin. Oncogene 17,173-178
57. Suh, H.-W., Kang, S., and Kwon, K.-S. (2007) Cur cumin attenuates glutamate-induced HT22 cell death by suppressing MAP kinase signaling. Mol. Cell. Biochem. 298,187-194
58. Truelove, S. C., and Witts, L. (1955) Cortisone in ulcerative colitis. Br. Med.J. 2,1041-1048
59. Feuerstein, J. D., and Cheifetz, A. S. (2014) Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin. Proc. 10.1016/j.mayocp.2014.07.002